Form 8-K - Current report:
SEC Accession No. 0001213900-22-074041
Filing Date
2022-11-21
Accepted
2022-11-21 09:15:22
Documents
14
Period of Report
2022-11-21
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea169007-8k_citiuspharma.htm   iXBRL 8-K 29863
2 PRESS RELEASE DATED NOVEMBER 21, 2022 ea169007ex99-1_citius.htm EX-99.1 13717
3 GRAPHIC ex99-1_001.jpg GRAPHIC 4472
  Complete submission text file 0001213900-22-074041.txt   227739

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE ctxr-20221121.xsd EX-101.SCH 3239
5 XBRL LABEL FILE ctxr-20221121_lab.xml EX-101.LAB 34240
6 XBRL PRESENTATION FILE ctxr-20221121_pre.xml EX-101.PRE 22367
8 EXTRACTED XBRL INSTANCE DOCUMENT ea169007-8k_citiuspharma_htm.xml XML 3598
Mailing Address 11 COMMERCE DRIVE 1ST FLOOR CRANFORD NJ 07016
Business Address 11 COMMERCE DRIVE 1ST FLOOR CRANFORD NJ 07016 (908) 967-6676
Citius Pharmaceuticals, Inc. (Filer) CIK: 0001506251 (see all company filings)

EIN.: 273425913 | State of Incorp.: NV | Fiscal Year End: 0930
Type: 8-K | Act: 34 | File No.: 001-38174 | Film No.: 221403723
SIC: 2834 Pharmaceutical Preparations